Oscar J Cordero1, Rubén Varela-Calviño2, Tania López-González2, Milica Grujic3, Zorica Juranic4, Coral Mouriño5, Íñigo Hernández-Rodríguez6, Marina Rodríguez-López5, Bruno Aspe de la Iglesia6, José María Pego-Reigosa5. 1. Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: oscarj.cordero@usc.es. 2. Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain. 3. Institute of Rheumatology, Belgrade, Serbia. 4. Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia. 5. Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain; IRIDIS (Investigation in Rheumatology and Immuno-mediated Diseases) Group, Instituto de Investigación Biomédica, Xerencia de Xestión Integrada de Vigo/Pontevedra/Ourense-SERGAS, Spain. 6. Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain.
Abstract
OBJECTIVES: Rheumatoid arthritis (RA) patients show low serum levels of the Ag dipeptidyl peptidase IV (DPP-IV/CD26), both soluble CD26 (sCD26) concentration and its DPP-IV activity. The aim of this study was to test if anti-DPP-IV/CD26 Abs (Anti-CD26) cleared sCD26. DESIGN & METHODS: Serum Anti-CD26 and Total titers (as comparison) of isotypes IgA, IgM and IgG as well as sCD26 concentration and DPP-IV activity were measured in a cohort of RA patients undergoing different biological and non-biological therapies (n=105) and controls (n=50). RESULTS: Anti-CD26 levels were increased approximately two-fold for each isotype in RA, were not related to the sCD26 clearance, showed several correlations with disease activity parameters, were significantly higher in smokers and they were not ACPA. Anti-CD26 Igs showed high diagnostic power (82% sensitivity and 96% specificity) and their levels differed amongst the different groups of patients stratified by the type of therapy. CONCLUSIONS: As DPP-IV/CD26 is associated to factors triggering RA in the lung and periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.
OBJECTIVES:Rheumatoid arthritis (RA) patients show low serum levels of the Ag dipeptidyl peptidase IV (DPP-IV/CD26), both soluble CD26 (sCD26) concentration and its DPP-IV activity. The aim of this study was to test if anti-DPP-IV/CD26 Abs (Anti-CD26) cleared sCD26. DESIGN & METHODS: Serum Anti-CD26 and Total titers (as comparison) of isotypes IgA, IgM and IgG as well as sCD26 concentration and DPP-IV activity were measured in a cohort of RApatients undergoing different biological and non-biological therapies (n=105) and controls (n=50). RESULTS: Anti-CD26 levels were increased approximately two-fold for each isotype in RA, were not related to the sCD26 clearance, showed several correlations with disease activity parameters, were significantly higher in smokers and they were not ACPA. Anti-CD26 Igs showed high diagnostic power (82% sensitivity and 96% specificity) and their levels differed amongst the different groups of patients stratified by the type of therapy. CONCLUSIONS: As DPP-IV/CD26 is associated to factors triggering RA in the lung and periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.
Authors: A Casrouge; A V Sauer; R Barreira da Silva; M Tejera-Alhambra; S Sánchez-Ramón; C Cancrini; M A Ingersoll; A Aiuti; M L Albert Journal: Clin Exp Immunol Date: 2018-09-24 Impact factor: 4.330
Authors: Loretta De Chiara; María Páez de la Cadena; Javier Rodríguez-Berrocal; Mª Carmen Alvarez-Pardiñas; Mª Carmen Pardiñas-Añón; Rubén Varela-Calviño; Oscar J Cordero Journal: Dis Markers Date: 2020-01-21 Impact factor: 3.434
Authors: Oscar J Cordero; Carlos Rafael-Vidal; Rubén Varela-Calviño; Cristina Calviño-Sampedro; Beatriz Malvar-Fernández; Samuel García; Juan E Viñuela; José M Pego-Reigosa Journal: Biomolecules Date: 2021-10-02